China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Scheduled to Reverse Split on Monday, August 10th

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC)’s stock is scheduled to reverse split before the market opens on Monday, August 10th. The 1-80 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 9th.

China SXT Pharmaceuticals Stock Performance

Shares of China SXT Pharmaceuticals stock traded down $0.01 on Thursday, reaching $0.05. 46,705,100 shares of the company were exchanged, compared to its average volume of 15,593,663. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. China SXT Pharmaceuticals has a one year low of $0.05 and a one year high of $1,046.98. The company has a 50-day moving average of $1.76 and a 200 day moving average of $2.66.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its earnings results on Wednesday, July 1st. The company reported ($0.07) earnings per share for the quarter. The company had revenue of $0.26 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

Large investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new position in China SXT Pharmaceuticals during the 4th quarter worth $36,000. Virtu Financial LLC raised its stake in China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in China SXT Pharmaceuticals in the 3rd quarter valued at about $78,000. Institutional investors own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.